Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new drug sharpen the minds of people with schizophrenia?

NCT ID NCT07084831

Not yet recruiting Symptom relief Sponsor: European Group for Research In Schizophrenia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a new medicine, Xanomeline/Trospium (also called KarXT), can improve thinking and memory in adults with schizophrenia. Unlike standard antipsychotics, this drug targets a different brain system and may help with cognitive symptoms. Researchers will follow 171 participants for up to a year, measuring changes in cognition, symptoms, and daily life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Xanomeline/Trospium (also known as KarXT/Cobenfy)
What this could lead to
If it works, this could show that Xanomeline/Trospium improves thinking and memory in people with schizophrenia, potentially leading to better daily functioning and quality of life.
What could go wrong
This is an early-phase, open-label study with no placebo group, so results may be less reliable. Cognitive improvements are not guaranteed, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Psychotic Disorders schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COGNITIVE IMPAIRMENT SCHIZOPHRENIA; PSYCHOSIS

Contacts and locations

Locations

  • AOU Città della Salute e della Scienza di Torino

    Torino, 10126, Italy

  • Central Institute of Mental Health

    Mannheim, 68159, Germany

  • Hospital Clínic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, 41013, Spain

  • Ludwig Maximilian University

    München, 80336, Germany

  • Medical University Innsbruck

    Innsbruck, 6020, Austria

  • National Institute of Mental Health

    Klecany, 250 67, Czechia

  • Psykiatrisk Center Glostrup

    Glostrup Municipality, 2600, Denmark

  • Semmelweis University

    Budapest, 1083, Hungary

  • Sheba Medical Center

    Ramat Gan, Israel

  • UPC KU Leuven

    Leuven, 3070, Belgium

  • University Hospital Cologne

    Cologne, 50937, Germany

  • University Medical Center Groningen

    Groningen, Netherlands

  • University of Augsburg

    Augsburg, 86156, Germany

  • University of Campania Luigi Vanvitelli

    Naples, 80138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.